MRK

Merck & Co., Inc. · Healthcare · Drug Manufacturers - General
$120.80
-3.23 (-2.60%)
Mkt Cap: 298.35B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield4.7%
Dividend YieldN/A
Market Cap298.35B
Volume9.08M
Recent News
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
businesswire.com · 2026-07-15
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
zacks.com · 2026-07-13
Why Merck Stock Is in the Spotlight Today
benzinga.com · 2026-07-13
Merck (MRK) Stock Sinks As Market Gains: Here's Why
zacks.com · 2026-07-10
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
businesswire.com · 2026-07-10
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com · 2026-07-10

Unlock the Full Deep Scan

9 AI agents analyze MRK across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →